Survival Outcomes After Adding Stereotactic Body Radiotherapy to Metastatic Renal Cell Carcinoma Patients Treated With Tyrosine Kinase Inhibitors

Long-lasting control is rarely achieved with tyrosine kinase inhibitors (TKI) alone in metastatic renal cell carcinoma (mRCC). Our study aimed to investigate the survival outcomes of adding stereotactic body radiotherapy (SBRT) to TKI in mRCC. MATERIALS AND METHODS: From September 2015 to September...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Am J Clin Oncol
Hlavní autoři: He, Liru, Liu, Yang, Han, Hui, Liu, Zhuowei, Huang, Sijuan, Cao, Wufei, Liu, Boji, Qin, Zike, Guo, Shengjie, Zhang, Zhiling, Lin, Maosheng, Jiang, Xiaobo, Lin, Chengguang, Li, Yonghong, Yao, Kai, Dong, Pei, Zhou, Fangjian
Médium: Artigo
Jazyk:Inglês
Vydáno: Lippincott Williams & Wilkins 2020
Témata:
Original Articles: Genitourinary
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6922069/
https://ncbi.nlm.nih.gov/pubmed/31651452
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/COC.0000000000000622
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky